Liu Juan, Wu Chang-Ping, Lu Bin-Feng, Jiang Jing-Ting
Department of Tumor Biological Treatment, The Third Affiliated Hospital of Soochow University, Changzhou 213003, China;
Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261, USA.
Cancer Biol Med. 2013 Sep;10(3):131-7. doi: 10.7497/j.issn.2095-3941.2013.03.002.
MicroRNAs (miRNAs) are small, non-coding single-stranded RNAs that can modulate target gene expression at post-transcriptional level and participate in cell proliferation, differentiation, and apoptosis. T cells have important functions in acquired immune response; miRNAs regulate this immune response by targeting the mRNAs of genes involved in T cell development, proliferation, differentiation, and function. For instance, miR-181 family members function in progression by targeting Bcl2 and CD69, among others. MiR-17 to miR-92 clusters function by binding to CREB1, PTEN, and Bim. Considering that the suppression of T cell-mediated immune responses against tumor cells is involved in cancer progression, we should investigate the mechanism by which miRNA regulates T cells to develop new approaches for cancer treatment.
微小RNA(miRNA)是一类小的、非编码单链RNA,可在转录后水平调节靶基因表达,并参与细胞增殖、分化和凋亡。T细胞在获得性免疫反应中发挥重要作用;miRNA通过靶向参与T细胞发育、增殖、分化和功能的基因的mRNA来调节这种免疫反应。例如,miR-181家族成员通过靶向Bcl2和CD69等发挥作用。miR-17至miR-92簇通过与CREB1、PTEN和Bim结合发挥作用。鉴于T细胞介导的针对肿瘤细胞的免疫反应的抑制与癌症进展有关,我们应该研究miRNA调节T细胞的机制,以开发新的癌症治疗方法。